$14.63
+18%ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Last Annual Value
10.77M
3-Year CAGR
17%
5-Year CAGR
27%
10-Year CAGR
3%
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
![]() ClearPoint Neuro, Inc. NASDAQ:CLPT | 10.77M | 13.2% | 17.8% | 13.6% | |
![]() Avanos Medical, Inc. NYSE:AVNS | 165.20M | -11.0% | 3.5% | -6.5% | |
![]() Akebia Therapeutics, Inc. NASDAQ:AKBA | 162.94M | 17.7% | -9.0% | 3.6% | |
![]() Surmodics, Inc. NASDAQ:SRDX | 20.54M | -5.0% | -7.2% | 7.3% | |
![]() Varex Imaging Corporation NASDAQ:VREX | 187.20M | 4.8% | 2.4% | N/A | |
![]() Cytek Biosciences, Inc. NASDAQ:CTKB | 77.80M | 11.4% | 18.6% | N/A | |
![]() Orthofix Medical Inc. NASDAQ:OFIX | 170.48M | 1.0% | 10.0% | 7.4% | |
![]() Standard BioTools Inc. NASDAQ:LAB | 108.31M | -0.3% | 16.9% | 13.9% | |
![]() SI-BONE, Inc. NASDAQ:SIBN | 25.28M | 2.5% | 8.4% | 6.6% |
Continue your CLPT research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.